Suppr超能文献

原发性硬化性胆管炎患者主胆管狭窄的诊断和治疗策略的分析综述。

Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis.

机构信息

Section of Hepatopancreaticobiliary and Transplant Surgery, McGill University Health Centre, Montreal, Canada.

出版信息

HPB (Oxford). 2011 Feb;13(2):79-90. doi: 10.1111/j.1477-2574.2010.00268.x.

Abstract

BACKGROUND

The diagnosis and treatment of indeterminate dominant strictures (DS) in patients with primary sclerosing cholangitis (PSC) is challenging and the literature on the subject is scarce.

OBJECTIVES

This review aims to appraise and synthesize the evidence published in the English-language medical literature on this topic.

METHODS

Scientific papers published from 1950 until week 4 of July 2010 were extracted from MEDLINE, Ovid Medline In-Process, the Cochrane Database of Systematic Reviews, the Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, EMBASE, PubMed and the National Library of Medicine Gateway.

RESULTS

Strategies for the optimal management of DS in PSC patients are supported only by level II and III evidence. Intraductal endoscopic ultrasound appears to be the most sensitive (64%) and specific (95%) diagnostic test for the evaluation of DS in PSC. Endoscopic and percutaneous dilatations achieve 1- and 3-year palliation in 80% and 60% of patients, respectively. Although dilatation and stenting are the most common palliative interventions in DS, no randomized trials on the optimal duration of treatment have been conducted.

CONCLUSIONS

In benign DS, endoscopic dilatation with short-term stenting seems to be effective and safe and does not increase the risks for malignant transformation or complications after liver transplantation. Surgical bile duct resection and/or bilioenteric bypass are indicated only in patients with preserved liver function.

摘要

背景

原发性硬化性胆管炎(PSC)患者的不定型优势狭窄(DS)的诊断和治疗具有挑战性,且该主题的文献很少。

目的

本综述旨在评估和综合发表在英文医学文献中的该主题证据。

方法

从 MEDLINE、Ovid Medline In-Process、Cochrane 系统评价数据库、系统评价数据库、疗效评价文摘数据库、EMBASE、PubMed 和美国国家医学图书馆网关提取 1950 年至 2010 年 7 月第 4 周发表的科学论文。

结果

仅为 PSC 患者 DS 的最佳管理策略提供了 II 级和 III 级证据。腔内超声内镜检查似乎是评估 PSC 中 DS 的最敏感(64%)和最特异(95%)的诊断性检查。内镜和经皮扩张术分别使 80%和 60%的患者在 1 年和 3 年内获得缓解。尽管扩张和支架置入术是 DS 中最常见的姑息性干预措施,但尚未进行关于最佳治疗持续时间的随机试验。

结论

在良性 DS 中,内镜扩张伴短期支架置入似乎有效且安全,并且不会增加恶性转化或肝移植后并发症的风险。只有在肝功能正常的患者中,才需要进行手术胆管切除和/或胆肠旁路。

相似文献

2
Biliary stent therapy for dominant strictures in patients affected by primary sclerosing cholangitis.
Pathobiology. 2013;80(4):182-93. doi: 10.1159/000347057. Epub 2013 May 6.
3
The current diagnosis and treatment of benign biliary stricture.
Surg Today. 2012 Dec;42(12):1143-53. doi: 10.1007/s00595-012-0333-3. Epub 2012 Sep 22.
5
6
Common controversies in management of biliary strictures.
World J Gastroenterol. 2017 Feb 21;23(7):1119-1124. doi: 10.3748/wjg.v23.i7.1119.
8
Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis.
Endoscopy. 2006 Jul;38(7):665-9. doi: 10.1055/s-2006-925257. Epub 2006 Apr 27.
9
Endoscopic treatment of primary sclerosing cholangitis.
Turk J Gastroenterol. 2004 Sep;15(3):144-8.
10
No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis.
Gastroenterology. 2018 Sep;155(3):752-759.e5. doi: 10.1053/j.gastro.2018.05.034. Epub 2018 May 24.

引用本文的文献

3
Klatskin-Mimicking Lesions.
Diagnostics (Basel). 2021 Oct 20;11(11):1944. doi: 10.3390/diagnostics11111944.
4
Predictors of Jaundice Resolution and Survival After Endoscopic Treatment of Primary Sclerosing Cholangitis.
Hepatol Commun. 2022 Apr;6(4):809-820. doi: 10.1002/hep4.1813. Epub 2021 Sep 1.
7
Clinical guidelines for primary sclerosing cholangitis 2017.
J Gastroenterol. 2018 Sep;53(9):1006-1034. doi: 10.1007/s00535-018-1484-9. Epub 2018 Jun 27.
8
The Detection of Cholangiocarcinoma in Primary Sclerosing Cholangitis Patients: Single Center Experience.
J Gastrointest Cancer. 2016 Mar;47(1):8-14. doi: 10.1007/s12029-015-9777-1.
9
What is the current role of endoscopy in primary sclerosing cholangitis?
World J Gastrointest Endosc. 2015 Aug 10;7(10):920-7. doi: 10.4253/wjge.v7.i10.920.
10
Diagnosis and management of primary sclerosing cholangitis-perspectives from a therapeutic endoscopist.
World J Hepatol. 2015 Apr 18;7(5):799-805. doi: 10.4254/wjh.v7.i5.799.

本文引用的文献

1
Primary sclerosing cholangitis: the role of extrahepatic biliary resection.
Adv Surg. 2009;43:175-88. doi: 10.1016/j.yasu.2009.02.015.
4
Surgical approaches to strictures in primary sclerosing cholangitis.
J Gastrointest Surg. 2008 Mar;12(3):423-5. doi: 10.1007/s11605-007-0342-5. Epub 2007 Oct 20.
5
Current treatments of primary sclerosing cholangitis.
Curr Med Chem. 2007;14(19):2081-94. doi: 10.2174/092986707781368388.
6
Guidelines for therapy of autoimmune liver disease.
Semin Liver Dis. 2007 May;27(2):214-26. doi: 10.1055/s-2007-979472.
7
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Curr Gastroenterol Rep. 2007 Mar;9(1):54-9. doi: 10.1007/s11894-008-0021-z.
8
Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures.
Gastroenterology. 2006 Oct;131(4):1064-72. doi: 10.1053/j.gastro.2006.08.021. Epub 2006 Aug 16.
9
Primary sclerosing cholangitis: summary of a workshop.
Hepatology. 2006 Sep;44(3):746-64. doi: 10.1002/hep.21337.
10
Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis.
J Hepatol. 2006 Oct;45(4):568-74. doi: 10.1016/j.jhep.2006.05.010. Epub 2006 Jun 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验